Overview
Lysine (abbreviated as Lys or K) is an α-amino acid with the chemical formula HO2CCH(NH2)(CH2)4NH2. This amino acid is an essential amino acid, which means that humans cannot synthesize it. Its codons are AAA and AAG. Lysine is a base, as are arginine and histidine. The ε-amino group acts as a site for hydrogen binding and a general base in catalysis. Common posttranslational modifications include methylation of the ε-amino group, giving methyl-, dimethyl-, and trimethyllysine. The latter occurs in calmodulin. Other posttranslational modifications include acetylation. Collagen contains hydroxylysine which is derived from lysine by lysyl hydroxylase. O-Glycosylation of lysine residues in the endoplasmic reticulum or Golgi apparatus is used to mark certain proteins for secretion from the cell.
Indication
Supplemental lysine has putative anti-herpes simplex virus activity. There is preliminary research suggesting that it may have some anti-osteoporotic activity.
Associated Conditions
- Weight Loss
Research Report
Comprehensive Monograph on L-Lysine (DB00123)
Section 1: Molecular Profile and Physicochemical Characteristics
This section provides a definitive characterization of L-lysine, establishing its fundamental chemical identity, structural properties, and physical characteristics. This foundational knowledge is essential for understanding its complex biological roles, pharmacological activities, and applications in clinical and industrial settings.
1.1 Identification and Nomenclature
L-lysine is a small molecule classified as an essential α-amino acid.[1] Its unambiguous identification is critical for scientific research, regulatory affairs, and commercial use. The molecule is cataloged across numerous international chemical and biological databases under a consistent set of identifiers. The primary and most widely recognized CAS Registry Number for L-lysine is 56-87-1.[2] Its unique DrugBank Accession Number is DB00123, which links it to a wealth of curated pharmacological and biochemical data.[1]
The systematic name for the molecule, according to the International Union of Pure and Applied Chemistry (IUPAC), is (2S)-2,6-diaminohexanoic acid, which precisely describes its structure as a six-carbon hexanoic acid with amino groups at the second (α) and sixth (ε) positions, with the stereochemistry at the α-carbon specified as 'S'.[2] Its molecular formula is consistently reported as $C_6H_{14}N_2O_2$, and its molecular weight is approximately 146.19 g/mol.[2]
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/08/30 | Phase 2 | Recruiting | |||
2024/04/23 | Phase 1 | Recruiting | |||
2022/01/27 | Phase 1 | Completed | |||
2018/02/27 | Early Phase 1 | Completed | |||
2018/02/22 | Early Phase 1 | Completed | |||
2017/02/24 | Phase 1 | Completed | |||
2016/10/11 | Phase 2 | UNKNOWN | Fundacion Investigacion Interhospitalaria Cardiovascular | ||
2016/04/29 | Phase 1 | Completed | |||
2014/09/17 | Phase 1 | Completed | David Vivas | ||
2013/09/05 | Phase 4 | UNKNOWN | Azienda Ospedaliera San Giovanni Battista |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Baxter Healthcare Corporation | 0338-0184 | INTRAVENOUS | 464 mg in 100 mL | 4/13/2021 | |
| Baxter Healthcare Company | 0338-0210 | INTRAVENOUS | 464 mg in 100 mL | 9/21/2020 | |
| Baxter Healthcare Corporation | 0338-0210 | INTRAVENOUS | 464 mg in 100 mL | 9/21/2020 | |
| Baxter Healthcare Corporation | 0338-1089 | INTRAVENOUS | 247 mg in 100 mL | 4/13/2021 | |
| Baxter Healthcare Corporation | 0338-1099 | INTRAVENOUS | 290 mg in 100 mL | 4/13/2021 | |
| ICU Medical Inc. | 0990-7171 | INTRAVENOUS | 1575 mg in 100 mL | 5/4/2022 | |
| Baxter Healthcare Corporation | 0338-0194 | INTRAVENOUS | 464 mg in 100 mL | 4/13/2021 | |
| Baxter Healthcare Company | 0338-1147 | INTRAVENOUS | 290 mg in 100 mL | 9/21/2020 | |
| Baxter Healthcare Corporation | 0338-1147 | INTRAVENOUS | 290 mg in 100 mL | 9/21/2020 | |
| Baxter Healthcare Company | 0338-1142 | INTRAVENOUS | 159 mg in 100 mL | 9/21/2020 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 7/25/2019 | ||
Authorised | 7/25/2019 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| LYSAKARE SOLUTION FOR INFUSION 25G / 25G | SIN16003P | INFUSION, SOLUTION | 25 g/L | 8/31/2020 | |
| OLICLINOMEL N4-550 E EMULSION FOR INFUSION | SIN12542P | EMULSION | 1.60 g/l | 5/6/2004 | |
| SmofKabiven Emulsion for Infusion | SIN14286P | INJECTION, EMULSION | 9.3g /1000ml | 1/8/2013 | |
| KABIVEN PERIPHERAL EMULSION FOR INFUSION | SIN11718P | INJECTION | 1.9 g/l | 11/16/2001 | |
| OLICLINOMEL N7-1000 E EMULSION FOR INFUSION | SIN12539P | EMULSION | 2.90 g/l | 5/6/2004 | |
| NUTRIFLEX® OMEGA PLUS EMULSION FOR INFUSION | SIN15468P | INJECTION, EMULSION | 2.728g/1000ml | 4/23/2018 | |
| PERIOLIMEL N4E Emulsion for Infusion | SIN16888P | EMULSION | 1.99g/L | 10/20/2023 | |
| TROPHAMINE INJECTION 10% | SIN07846P | INJECTION | 0.82 g/100 ml | 9/12/1994 | |
| AMINOPLASMAL B.BRAUN 10% E SOLUTION FOR INFUSION | SIN15411P | INFUSION, SOLUTION | 8.56g/1000ml | 1/23/2018 | |
| NUTRIFLEX® OMEGA SPECIAL B. BRAUN EMULSION FOR INFUSION | SIN16734P | INJECTION, EMULSION | 3.980g/1000ml | 3/7/2023 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| VAMINOLACT I.V. SOLUTION | N/A | N/A | N/A | 10/14/1992 | |
| PAN-AMIN G INJ | N/A | N/A | N/A | 5/17/1979 | |
| PAN-AMIN G SOLUTION FOR INFUSION 500ML | N/A | otsuka pharmaceutical (h.k.) limited | N/A | N/A | 4/5/2012 |
| NUTRINEAL PD4 SOLUTION | N/A | N/A | N/A | 9/9/1999 | |
| LA-FLAMING INJ. | N/A | N/A | N/A | 1/28/2010 | |
| OLIMEL N9E EMULSION FOR INFUSION | N/A | N/A | N/A | 10/24/2013 | |
| NUTRIFLEX OMEGA SPECIAL EMULSION FOR INFUSION | N/A | N/A | N/A | 1/11/2012 | |
| SMOFKABIVEN EMULSION FOR INFUSION | N/A | N/A | N/A | 5/26/2011 | |
| NUTRIFLEX OMEGA PLUS EMULSION FOR INFUSION | N/A | N/A | N/A | 1/11/2012 | |
| AMINOGEN-S SOLUTION FOR INFUSION | N/A | wings pharmaceutical ltd | N/A | N/A | 8/15/2013 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| Cellula-T oral powder jar | 43995 | Hong Sp & Hs | Medicine | A | 4/13/1993 |
| SYNTHAMIN 17 Amino acid 10% with Electrolytes and Glucose 25% 1000mL injection AHB6350 | 19609 | Medicine | A | 9/30/1991 | |
| AMINOVEN amino acid 10% solution for infusion 500 mL bottle | 117659 | Medicine | A | 10/22/2007 | |
| SMOFKABIVEN amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 1970 mL | 180546 | Medicine | A | 1/9/2012 | |
| Kids Multi | 329564 | Medicine | A | 2/6/2020 | |
| OLICLINOMEL N4-550 E 1000 mL IV emulsion for infusion with electrolytes bag | 136599 | Medicine | A | 9/4/2007 | |
| OLICLINOMEL N4-550 E 2500 mL IV emulsion for infusion with electrolytes bag | 141396 | Medicine | A | 9/4/2007 | |
| OLIMEL N5-860E Emulsion for intravenous infusion | 197417 | Medicine | A | 8/9/2013 | |
| Visdon BRAINBOOK Concentration Support | 371690 | Medicine | A | 7/27/2021 | |
| Olimel N12-640 emulsion for intravenous infusion bag. | 303755 | Medicine | A | 7/1/2019 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| 2.5% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE CLINIMIX | baxter corporation clintec nutrition division | 02013975 | Solution - Intravenous | 145 MG / 100 ML | 12/31/1993 |
| CLINIMIX E | baxter corporation | 02013967 | Solution - Intravenous | 290 MG / 100 ML | 12/31/1993 |
| TRAVASOL INJ WITHOUT ELECTROLYTES 5.5% | baxter corporation | 00388742 | Solution - Intravenous | 318 MG / 100 ML | 12/31/1978 |
| PRIMENE 10%-LIQ IV | clintec nutrition company | 02161192 | Liquid - Intravenous | 1.1 G / 100 ML | 12/31/1995 |
| METABOLINE | desbergers ltée, division of technilab inc. | 00086878 | Tablet - Oral | 100 MG | 12/31/1967 |
| RENAMIN (AMINO ACIDS) INJECTION | baxter corporation | 02020564 | Solution - Intravenous | 450 MG / 100 ML | 2/2/1996 |
| PRIMENE 10% | baxter corporation | 02236875 | Liquid - Intravenous | 1.1 G / 100 ML | 11/14/1997 |
| CLINIMIX | baxter corporation | 02013916 | Solution - Intravenous | 246 MG / 100 ML | 12/31/1993 |
| 4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 5% DEXTROSE QUICKMIX | baxter corporation clintec nutrition division | 02014017 | Solution - Intravenous | 246 MG / 100 ML | 12/31/1995 |
| TRAVASOL | baxter corporation | 00388769 | Solution - Intravenous | 580 MG / 100 ML | 12/31/1980 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.
